Initial Performance of NI-RADS to Predict Residual or Recurrent Head and Neck Squamous Cell Carcinoma

被引:49
|
作者
Krieger, D. A. [1 ]
Hudgins, P. A. [2 ]
Nayak, G. K. [7 ]
Baugnon, K. L. [2 ]
Corey, A. S. [2 ]
Patel, M. R. [3 ]
Beitler, J. J. [3 ,4 ,5 ]
Saba, N. F. [5 ]
Liu, Y. [6 ]
Aiken, A. H. [2 ]
机构
[1] Hackensack Univ Med Ctr, Dept Radiol, Hackensack, NJ USA
[2] Emory Univ, Sch Med, Dept Radiol & Imaging Sci, Atlanta, GA USA
[3] Emory Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Atlanta, GA USA
[4] Emory Univ, Sch Med, Winship Canc Inst, Dept Radiat Oncol, Atlanta, GA USA
[5] Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA USA
[6] Emory Univ, Sch Med, Dept Biostat, Winship Canc Inst, Atlanta, GA USA
[7] NYU, Dept Radiol, Sch Med, 560 1st Ave, New York, NY 10016 USA
关键词
SURVEILLANCE PET/CT; CANCER; UTILITY;
D O I
10.3174/ajnr.A5157
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND PURPOSE: The Head and Neck Imaging Reporting and Data System (NI-RADS) surveillance template for head and neck cancer includes a numeric assessment of suspicion for recurrence (1-4) for the primary site and neck. Category 1 indicates no evidence of recurrence; category 2, low suspicion of recurrence; category 3, high suspicion of recurrence; and category 4, known recurrence. Our purpose was to evaluate the performance of the NI-RADS scoring system to predict local and regional disease recurrence or persistence. MATERIALS AND METHODS: This study was classified as a quality-improvement project by the institutional review board. A retrospective database search yielded 500 consecutive cases interpreted using the NI-RADS template. Cases without a numeric score, non-squamous cell carcinoma primary tumors, and primary squamous cell carcinoma outside the head and neck were excluded. The electronic medical record was reviewed to determine the subsequent management, pathology results, and outcome of clinical and radiologic follow-up. RESULTS: A total of 318 scans and 618 targets (314 primary targets and 304 nodal targets) met the inclusion criteria. Among the 618 targets, 85.4% were scored NI-RADS 1; 9.4% were scored NI-RADS 2; and 5.2% were scored NI-RADS 3. The rates of positive disease were 3.79%, 17.2%, and 59.4% for each NI-RADS category, respectively. Univariate association analysis demonstrated a strong association between the NI-RADS score and ultimate disease recurrence, with P < .001 for primary and regional sites. CONCLUSIONS: The baseline performance of NI-RADS was good, demonstrating significant discrimination among the categories 1-3 for predicting disease.
引用
收藏
页码:1193 / 1199
页数:7
相关论文
共 50 条
  • [41] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, H-F.
    Hong, R-L.
    ANNALS OF ONCOLOGY, 2018, 29 : 379 - 379
  • [42] Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck
    Arnold, DJ
    Goodwin, WJ
    Weed, DT
    Civantos, FJ
    SEMINARS IN RADIATION ONCOLOGY, 2004, 14 (02) : 190 - 195
  • [43] Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck
    Recchia, Francesco
    Candeloro, Giampiero
    Di Staso, Mario
    Necozione, Stefano
    Bisegna, Roberta
    Bratta, Massimo
    Tombolini, Vincenzo
    Rea, Silvio
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (04) : 413 - 419
  • [44] Outpatient chemotherapy for recurrent and/or advanced squamous cell carcinoma of the head and neck
    Kohno N.
    Kitahara S.
    Kawaida M.
    Ichikawa G.
    Shirasaka T.
    International Journal of Clinical Oncology, 1999, 4 (5) : 285 - 288
  • [45] Pain as sign of recurrent disease in head and neck squamous cell carcinoma
    Smit, M
    Balm, AJM
    Hilgers, FJM
    Tan, IB
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (05): : 372 - 375
  • [46] Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck
    Constenla, DO
    Hill, ME
    AHern, RP
    Henk, JM
    RhysEvans, P
    Breach, N
    Archer, D
    Gore, ME
    ANNALS OF ONCOLOGY, 1997, 8 (05) : 445 - 449
  • [47] Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma
    Hedberg, Matthew L.
    Goh, Gerald
    Chiosea, Simion I.
    Bauman, Julie E.
    Freilino, Maria L.
    Zeng, Yan
    Wang, Lin
    Diergaarde, Brenda B.
    Gooding, William E.
    Lui, Vivian W. Y.
    Herbst, Roy S.
    Lifton, Richard P.
    Grandis, Jennifer R.
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (01): : 169 - 180
  • [48] Initial staging examinations for head and neck squamous cell carcinoma: are they appropriate?
    Andrle, J.
    Schartinger, V. H.
    Schwentner, I.
    Deibl, M.
    Sprinzl, G. M.
    JOURNAL OF LARYNGOLOGY AND OTOLOGY, 2009, 123 (08): : 885 - 888
  • [49] Initial work-up in head and neck squamous cell carcinoma
    Hamoir, M.
    Vander Poorten, V.
    Chantrain, G.
    Van Laer, C.
    Gasmanne, P.
    Deron, R.
    B-ENT, 2005, : 129 - 132
  • [50] Radioimmunotherapy in patients with head and neck squamous cell carcinoma: Initial experience
    Colnot, DR
    Quak, JJ
    Roos, JC
    de Bree, R
    Wilhelm, AJ
    Snow, GB
    van Dongen, GAMS
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2001, 23 (07): : 559 - 565